First Time Loading...

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 5.11 HKD -1.54% Market Closed
Updated: May 6, 2024

Alphamab Oncology
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alphamab Oncology
Net Income (Common) Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Alphamab Oncology
HKEX:9966
Net Income (Common)
-¥210.6m
CAGR 3-Years
21%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥13.6B
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1B
CAGR 3-Years
-1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥8.5B
CAGR 3-Years
40%
CAGR 5-Years
47%
CAGR 10-Years
45%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.3B
CAGR 3-Years
61%
CAGR 5-Years
73%
CAGR 10-Years
N/A

See Also

What is Alphamab Oncology's Net Income (Common)?
Net Income (Common)
-210.6m CNY

Based on the financial report for Dec 31, 2023, Alphamab Oncology's Net Income (Common) amounts to -210.6m CNY.

What is Alphamab Oncology's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-7%

Over the last year, the Net Income (Common) growth was 35%. The average annual Net Income (Common) growth rates for Alphamab Oncology have been 21% over the past three years , -7% over the past five years .